Overview

Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer

Status:
Completed
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
Immunotherapy improved efficacy and survival in selective patients with metastatic colorectal cancer (mCRC), however, limited data revealed the landscape of immunotherapy efficacy. What's more, potential markers have not been comprehensively evaluated to identify responding patients to further improve efficacy.The investigators conducted a single-arm study to investigate the efficacy of combination immunotherapy in patients with mCRC, and the combined regimen is determined by the physician in charge.
Phase:
Phase 2
Details
Lead Sponsor:
First Affiliated Hospital of Zhejiang University